Ernexa Therapeutics Inc. Operating Lease Liability
Ernexa Therapeutics Inc. (ERNA) had Operating Lease Liability of $349.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability $349.00K.
- 2026-03-31: Operating Lease, Liability $389.00K.
- 2026-02-18: Operating Lease, Liability $26.00K.
- 2025-12-31: Operating Lease, Liability $490.00K.
| Period end | Operating Lease, Liability | Operating Lease, Liability as first filed |
|---|---|---|
| 2026-06-30 | $349.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $389.00K 10-Q · filed 2026-05-11 | |
| 2026-02-18 | $26.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $490.00K 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $552.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $593.00K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $632.00K 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $684.00K 10-K · filed 2026-03-13 | |
| 2024-09-30 | $735.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $40.31M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $39.44M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $35.07M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $36.15M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $35.14M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $1.01M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $1.18M 10-K · filed 2024-03-14 | |
| 2022-12-29 | $200.00K 10-K · filed 2023-03-20 | |
| 2022-09-30 | $2.75M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $2.82M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $1.50M 10-K · filed 2024-03-14 | $1.17M 10-Q · filed 2022-07-01 |
| 2022-03-25 | $1.50M 10-K · filed 2023-03-20 | |
| 2021-12-31 | $2.72M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $2.82M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $2.91M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $2.11M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $2.18M 10-K/A · filed 2022-07-01 | $36.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $5.00K 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $46.00K 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $3.17M 10-Q · filed 2020-05-20 | |
| 2019-12-31 | $3.30M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $3.40M 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $3.45M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $3.43M 10-Q · filed 2019-05-14 | |
| 2019-01-02 | $3.46M 10-K · filed 2021-03-11 | |
| 2018-12-31 | $3.46M 10-K · filed 2020-03-19 | $3.50M 10-K · filed 2019-03-22 |
| 2018-12-27 | $3.46M 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |